Aspen Neuroscience Inc, a private biotechnology company, announced on Tuesday that it has named Ana Sousa as its new senior vice president of regulatory affairs and quality, and as a member of the company's executive team.
Sousa has over 20 years of experience in global development and regulatory affairs combined. She has headed Global Regulatory Affairs and Quality for Principia Biopharma. She has held roles of increased leadership with Immune Design, Onyx Pharmaceuticals, and Genentech-Roche.
Sousa has her undergraduate degree from Pace University, Lubin School of Business, and Master of Science in Jurisprudence degree with a concentration in Health Law and Intellectual Property from The Seton Hall University School of Law.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer